CTOs on the Move

Water's Edge Dermatology

www.wederm.com

 
Waters Edge Dermatology treats pediatric, adult and senior skincare patients in warmly welcoming, well-appointed offices across South & Central Florida; providing medical, surgical & cosmetic dermatology services, and state-of-the-art skin cancer dete...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.wederm.com
  • 600, Village Square Crossing
    Palm Beach Gardens, FL USA 33410
  • Phone: 877.900.3223

Executives

Name Title Contact Details

Similar Companies

BN ImmunoTherapeutics

BN ImmunoTherapeutics is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BestSelf

A change for the Best is here! Child & Adolescent Treatment Services and Lake Shore Behavioral Health are proud to become BestSelf Behavioral Health!

Pharmaceutical Search Professionals Inc

Pharmaceutical Search Professionals Inc is a North Wales, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Athira

At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer`s, so that patients can regain their memories, lives, and family relationships. We are a motivated, impassioned team committed to making a positive impact on human health.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.